EVOK | Evoke Pharma, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.30 - 6.00
52 Week Range	3.54 - 17.88
Beta	-0.09
Implied Volatility	206.81%
IV Rank	47.09%
Day's Volume	64,157
Average Volume	419,540
Shares Outstanding	819,272
Market Cap	4,686,236
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2013-09-25

Valuation
Profitability
Growth
Health
P/E Ratio	-0.36
Forward P/E Ratio	N/A
EPS	-15.89
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	4
Country	USA
Website	EVOK

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

EVOK's peers: AQST, AVDL, AYTU, BFRI, CPIX, DERM, DRRX, PTPI, AGRX, PRFX, ADMP, GHSI, ACRX, EGRX, RGC, PROC, IXHL, JUPW, SHPH, AKAN, CPHI, KMDA, RDHL, RMTI, TXMD

*Chart delayed

Analyzing fundamentals for EVOK we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see EVOK Fundamentals page.

Watching at EVOK technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on EVOK Technicals page.